{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:55:16Z","timestamp":1790855716362,"version":"4.1.0"},"reference-count":15,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Colorectal cancer (CRC) is extremely rare in paediatrics with aggressive histopathology and advanced presentation. Whilst pembrolizumab has shown efficacy in adult microsatellite instability-high or mismatch repair deficiency CRC, paediatric data remain scarce. A 12-yearold boy with Lynch syndrome-associated CRC developed severe cardiac toxicity after initial chemotherapy. Treatment was switched to off-label pembrolizumab, resulting in a complete response after 24 cycles. Despite good tolerability, the patient developed a delayed bowel stricture at the tumour site. After surgery, there was no pathological evidence of residual adenocarcinoma. This case demonstrates the potential of pembrolizumab in paediatric CRC, highlighting the importance of molecular-guided rather than age-restricted therapy selection.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-complete-response-to-pembrolizumab-in-a-paediatric-patient-with-lynch-syndrome-associated-colorectal-cancer-a-case-report-and-review-of-immunotherapy-related-bowel-obstruction<\/jats:p>","DOI":"10.7573\/dic.2026-1-5","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:13:56Z","timestamp":1775672036000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Complete response to pembrolizumab in a paediatric patient with Lynch syndrome-associated colorectal cancer: a case report and review of immunotherapy-related bowel obstruction"],"prefix":"10.7573","author":[{"given":"Antonio","family":"Ruggiero","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fuccillo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Maurizi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Talloa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mastrangelo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Basso","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Briganti","sequence":"additional","affiliation":[{"name":"San Camillo Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Giustiniani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Persiani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rg70c39","id-type":"ROR","asserted-by":"publisher"}],"name":"Agostino Gemelli University Polyclinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Attin\u00e0","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tAttard TM, Lawson CE. Comparison of the demographic characteristics of pediatric and adult colorectal cancer patients: a national inpatient sample based analysis. World J Pediatr. 2019;15(1):37\u201341. https:\/\/doi.org\/10.1007\/ s12519-018-0187-x","DOI":"10.1007\/s12519-018-0187-x"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tPoles GC, Clark DE, Mayo SW, et al. Colorectal carcinoma in pediatric patients: a comparison with adult tumors, treatment and outcomes from the National Cancer Database. J Pediatr Surg. 2016;51(7):1061\u20131066. https:\/\/ doi.org\/10.1016\/j.jpedsurg.2015.11.005","DOI":"10.1016\/j.jpedsurg.2015.11.005"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPhen C, Berens D, Moriarty K, Ng K, Sengupta A, Rojas I. Polygenic early-onset colorectal cancer in pediatric patients. Pediatr Blood Cancer. 2022;69(10):e29790. https:\/\/doi.org\/10.1002\/pbc.29790","DOI":"10.1002\/pbc.29790"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tHuang SC, Durno CA, Erdman SH. Lynch syndrome: a pediatric perspective. J Pediatr Gastroenterol Nutr. 2014;58(2):144\u2013152. https:\/\/doi.org\/10.1097\/MPG.0000000000000179","DOI":"10.1097\/MPG.0000000000000179"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tBlumer SL, Anupindi SA, Adamson PC, et al. Sporadic adenocarcinoma of the colon in children: case series and review of the literature. J Pediatr Hematol Oncol. 2012;34(4):e137\u2013e141. https:\/\/doi.org\/10.1097\/MPH.0b013e3182467f3e","DOI":"10.1097\/MPH.0b013e3182467f3e"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tSpaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023;9(1):21. https:\/\/ doi.org\/10.1038\/s41572-023-00432-7","DOI":"10.1038\/s41572-023-00432-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tLe DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","DOI":"10.1126\/science.aan6733"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tDas R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950\u2013959. https:\/\/doi.org\/10.4049\/jimmunol.1401686","DOI":"10.4049\/jimmunol.1401686"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tLemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409\u20131412. https:\/\/doi.org\/10.1056\/NEJMp1709968","DOI":"10.1056\/NEJMp1709968"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tDiaz LA Jr, Shiu KK, Kim TW, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659\u2013670. https:\/\/doi.org\/10.1016\/ S1470-2045(22)00197-8","DOI":"10.1016\/S1470-2045(22)00197-8"},{"key":"ref10","unstructured":"11.\tAndre T, Elez E, Van Cutsem E, et al; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391(21):2014\u20132026. https:\/\/doi.org\/10.1056\/ NEJMoa2402141"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tPlatt JR, Allotey J, Alouani E, et al. Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series. ESMO Open. 2024;9(9):103698. https:\/\/doi.org\/10.1016\/ j.esmoop.2024.103698","DOI":"10.1016\/j.esmoop.2024.103698"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tSaif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191\u2013202. https:\/\/doi.org\/10.1517\/14740330902733961","DOI":"10.1517\/14740330902733961"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tJensen SA, Hasbak P, Mortensen J, et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010;28(36):5280\u20135286. https:\/\/doi.org\/10.1200\/JCO.2009.27.3953","DOI":"10.1200\/JCO.2009.27.3953"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tBaxi S, Yang A, Gennarelli RL, Khan N, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793. https:\/\/doi.org\/10.1136\/bmj.k793","DOI":"10.1136\/bmj.k793"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/04\/dic.2026-1-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:57:24Z","timestamp":1790852244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/complete-response-to-pembrolizumab-in-a-paediatric-patient-with-lynch-syndrome-associated-colorectal-cancer-a-case-report-and-review-of-immunotherapy-related-bowel-obstruction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-1-5","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"dic.2026-1-5"}}